Latest Adeno-associated virus Stories
AMSTERDAM, The Netherlands, September 18 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from Amgen to use their GDNF gene for the development of a gene therapy treatment for Parkinson's disease. The combination of this gene with AMT's proprietary adeno-associated virus (AAV) gene therapy platform could potentially allow the development of an effective, long-term treatment for...
Neurologix, a biotechnology company engaged in the development of gene therapies for the brain and central nervous system, and Aegera Therapeutics, a private clinical stage company focused on oncology and neuropathic pain, have executed an exclusive license agreement. Pursuant to the agreement, Neurologix has exclusively licensed the worldwide rights, excluding China, for the use of the x-linked inhibitor of apoptosis protein (XIAP) gene for therapeutic or prophylactic purposes in the...
Neurologix, Inc. (OTCBB: NRGX), a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, and Aegera Therapeutics, a private clinical stage company focused on oncology and neuropathic pain, announced today their execution of an exclusive license agreement. Pursuant to the agreement, Neurologix has exclusively licensed the worldwide rights, excluding China, for the use of the XIAP gene (x-linked inhibitor of apoptosis protein) for...
Targeted Genetics Corporation (NASDAQ: TGEN) will report its second quarter 2008 financial results before the open of the financial markets on Wednesday, August 6, 2008. Following the announcement, management will host a conference call and webcast discussion of the financial results and provide a general corporate update beginning at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time. You may access the live webcast via the "Events" section found on the homepage of the Company's website at:...
A recent study conducted by US researchers revealed that gene therapy could result in recession of a rare neurological disorder in children.Although lead researcher Dr. Ron Crystal of New York-Presbyterian Hospital/Weill Cornell Medical Center said the team of researchers was "encouraged by the study's results. "It's not a cure."Late infantile neuronal ceroidlipofuscinosis, or LINCL, is a neurodegenerative disease that affects the central nervous system in children. The disease usually...
PITTSBURGH, Oct. 25 "“ University of Pittsburgh investigators have for the first time used gene therapy to successfully treat heart failure and other degenerative muscle problems in an animal model that is genetically susceptible to a human muscular dystrophy. Reporting in the Oct. 25 edition of the journal Circulation, the authors say that this is the first successful attempt to deliver a therapeutic gene throughout the body. "Previous attempts at systemic gene therapy for muscle have...
WASHINGTON (Reuters) -- A common virus that is harmless to people can destroy cancerous cells in the body and might be developed into a new cancer therapy, U.S. researchers said on Tuesday.The virus, called adeno-associated virus type 2, or AAV-2, infects an estimated 80 percent of the population."Our results suggest that adeno-associated virus type 2, which infects the majority of the population but has no known ill effects, kills multiple types of cancer cells yet has no effect on...
PITTSBURGH, June 6 "“ Gene therapy for arthritis and other non-terminal, debilitating conditions and diseases is both feasible and safe, report researchers who conducted the world's first such test on the approach in patients with advanced rheumatoid arthritis. The results, published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS), indicate that introducing a new gene has the potential to block the destructive inflammation process that takes place...
